Note 5 - Supplemental disclosure for statement of cash flows

In the year ended July 31, 2024, interest paid by the Company approximated $395. In the year ended July 31, 2023, interest paid by the Company, including penalties and fees, approximated $1,246.

For the years ended July 31, 2024 and 2023, the net reductions in the measurement of right-of-use assets and liabilities included in cash flows from operating activities was approximately $366 and $38, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the consolidated statements of cash flows.

In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs at the end of fiscal 2023, $5,000 of escrowed proceeds are included in cash in escrow as of July 31, 2024 and in other assets as of July 31, 2023.

During the year ended July 31, 2024, state taxes paid on the gain on the sale of the Enzo Clinical Labs business was $730. For the year ended July 31, 2023, tax on capital paid by the Company was $22.

During the years ended July 31, 2024 and 2023, the Company issued common stock in connection with its share-based 401(k) employer match in the amount of $615 and $1,079, respectively.

During fiscal 2024, the Company issued 1,134,024 shares of common stock in settlement of Asset Purchase Agreement bonuses totaling $1,404 to an officer and a former officer.